It has been reported that CMTM6 protects programmed death-ligand-1 (PD-L1) from degradation by targeting it to the PM of cancer cells where it facilitates the immune evasion of cancer, including the immune evasion of CRC17,18. The gene discussed is CMTM6; the disease is cancer.